Equillium Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Equillium is de winst gegroeid met een gemiddeld jaarlijks percentage van 9%, terwijl de Biotechs industrie de winst jaarlijks groeide met 7.7%. De inkomsten zijn gegroeid met een gemiddelde van 76.9% per jaar.

Belangrijke informatie

9.0%

Groei van de winst

21.8%

Groei van de winst per aandeel

Biotechs Groei van de industrie	11.5%
Inkomstengroei	76.9%
Rendement op eigen vermogen	-19.9%
Nettomarge	-10.1%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Equillium geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

LSE:0A4D Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	46	-5	13	39
30 Jun 24	43	-8	14	39
31 Mar 24	38	-12	14	38
31 Dec 23	36	-13	14	37
30 Sep 23	43	-8	16	36
30 Jun 23	34	-18	16	36
31 Mar 23	25	-29	17	36
31 Dec 22	16	-62	17	38
30 Sep 22	0	-76	15	37
30 Jun 22	0	-72	13	35
31 Mar 22	0	-67	12	31
31 Dec 21	0	-39	11	26
30 Sep 21	0	-37	11	25
30 Jun 21	0	-34	10	23
31 Mar 21	0	-31	10	21
31 Dec 20	0	-30	10	19
30 Sep 20	0	-28	10	18
30 Jun 20	0	-28	10	18
31 Mar 20	0	-27	9	19
31 Dec 19	0	-26	9	18
30 Sep 19	0	-23	9	15
30 Jun 19	0	-22	7	12
31 Mar 19	0	-18	6	8
31 Dec 18	0	-13	4	5
30 Sep 18	0	-10	2	3

Kwaliteitswinsten: 0A4D is momenteel verliesgevend.

Groeiende winstmarge: 0A4D is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 0A4D is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 9% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 0A4D over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 0A4D is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -18.2% ).

Rendement op eigen vermogen

Hoge ROE: 0A4D heeft een negatief Return on Equity ( -19.91% ), omdat het momenteel verliesgevend is.

Equillium Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: US$0.013 (vs US$0.097 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

Recent updates

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: US$0.013 (vs US$0.097 loss in 2Q 2023)

New major risk - Financial position

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

New minor risk - Profitability

Forecast to breakeven in 2024

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Insufficient new directors

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Insufficient new directors

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Insufficient new directors

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

High number of new directors

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

High number of new directors

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of Cd6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Forecast to breakeven in 2025

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Equillium, Inc. Announces Positive Data Supporting the Role of Itolizumab as A Potential Treatment for Acute Graft-Versus-Host Disease

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

Equillium, Inc. Appoints Yu (Katherine) Xu, Ph.D., as A Class II Director

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 2000 Dynamic Index

Equillium, Inc. Appoints Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer, Effective January 11, 2021

Equillium Announces Positive Interim Data of Itolizumab in the First-Line Treatment of Acute Graft-Versus-Host Disease

Equillium, Inc. to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden